N-ethyl-N-(3,4-dichlorobenzyl)amine | 68621-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-ethyl-N-(3,4-dichlorobenzyl)amine
• 英文别名: (3,4-dichlorobenzyl)(ethyl)amine；(3,4-dichlorobenzyl)ethylamine；ethyl-(3,4-dichloro-benzyl)-amine；Aethyl-(3,4-dichlor-benzyl)-amin；Aethyl-<3,4-dichlor-benzyl>-amin；N-Ethyl-3,4-dichlorobenzylamin；N-(3,4-Dichlorobenzyl)ethanamine；N-[(3,4-dichlorophenyl)methyl]ethanamine
• CAS: 68621-16-9
• 化学式: C₉H₁₁Cl₂N
• mdl: MFCD00045168
• 分子量: 204.099
• InChiKey: DHWBKVYXMBSPIM-UHFFFAOYSA-N

物化性质

• 沸点：
  114-118 °C(Press: 4.0 Torr)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  N-ethyl-N-(3,4-dichlorobenzyl)amine 、 3-(4-methyl-6-dimethylaminopyridin-3-yl)-2,5-dimethyl-7-chloropyrazolo[1,5-a]pyrimidine 以 乙腈 为溶剂， 以48 mg的产率得到(3,4-Dichloro-benzyl)-[3-(6-dimethylamino-4-methyl-pyridin-3-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-ethyl-amine
  参考文献：
  名称：

  Design of 2,5-Dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and Structure−Activity Relationships of a Series of Potent and Orally Active Corticotropin-Releasing Factor Receptor Antagonists

  摘要：

  We have previously shown that 3-phenylpyrazolo[1,5-a]pyrimidines exemplified by 8 were potent antagonists of the human corticotropin-releasing factor-1 receptor. A series of 3-pyridylpyrazolo[1,5-a]pyrimidines 15, 25-30, 34, and 35 containing a weakly basic pyridine ring at the 3-position of the bicyclic nucleus was designed to reduce lipophilicity from the initial leads such as 7. Here, we showed that these 3-pyridyl compounds exhibited potent antagonists at the human CRF1, receptor. Moreover, the hydrophilic and weakly basic pyridine moiety increased the water solubility of some analogues. Compound 26h exhibited good binding affinity at the human CRF1 receptor with a K-i value of 3.5 nM. As a functional antagonist, it dose-dependently inhibited CRF-stimulated cAMP production in cells expressing the CRF1 receptor [IC50 = 50 nM), and CRF-stimulated ACTH release from cultured rat pituitary cells [IC50 = 20 nM). 26h had a log P value of 4.9 and water solubility of greater than 10 mg/mL. Pharmacokinetic studies in rats showed that 26h was orally bioavailable and able to penetrate into the brain. 26h has been demonstrated in vivo efficacy in animal behavioral models that measure anxiolytic activity. These results suggest that analogues from this series were potent CRF1, receptor antagonists with proper physicochemical properties and good pharmacokinetic profiles. 26h was developed into a clinical compound and exhibited efficacy in patients with major depression.

  DOI：

  10.1021/jm040058e
• 作为产物：
  描述：

  N-(3,4-Dichlor-benzyliden)-aethylamin 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 N-ethyl-N-(3,4-dichlorobenzyl)amine
  参考文献：
  名称：

  Benzylamines: synthesis and evaluation of antimycobacterial properties

  摘要：

  The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (19, MIC 10.2 micrograms/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 micrograms/mL), and N-butyl-3,5-difluorobenzylamine (103, MIC 6.4 micrograms/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combinations of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.

  DOI：

  10.1021/jm00375a005

文献信息

• Acetyl-CoA carboxylase inhibitors
  申请人：Pfizer Inc.

  公开号：US20030187254A1

  公开（公告）日：2003-10-02

  Acetyl Coenzyme A Carboxylase inhibitors, pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity.

  乙酰辅酶A羧化酶抑制剂，含有此类化合物的药物组合物，以及使用此类化合物治疗代谢综合征，包括动脉粥样硬化、糖尿病和肥胖等疾病。
• Synthesis and algicidal activity of new dichlorobenzylamine derivatives against harmful red tides
  作者：Dubok Choi、Sunjong Yu、Seung Ho Baek、Yoon-Ho Kang、Young-Cheol Chang、Hoon Cho

  DOI：10.1007/s12257-016-0175-8

  日期：2016.6

  In the present study, we synthesized 65 dichlorobenzylamine derivatives and investigated their algicidal activity against harmful red tides. The 3,4-dichlorobenzylamine derivatives showed relatively high activity against Cochlodinium polykrikoides, Heterosigma akashiwo, Chattonella marina, and Heterocapsa circularisquama, and the synthesized compounds 27, 28, 33, 34, 35, and 36 showed the highest algicidal activity after 24 h at 0.1 ~ 1.0 μM LC50 against the four harmful algae species. To verify the safety of the compounds, acute ecotoxicology tests using the water flea (Daphnia magna) and zebrafish (Danio rerio) were conducted, and the tests confirmed that compounds 33 and 34 were not harmful because the target organisms showed high survival rates at 15 μM. The results indicate that compounds 33 and 34 are suitable substances for use in controlling harmful algae species.

  在本研究中，我们合成了65种二氯苄胺衍生物，并研究了它们对有害赤潮的藻类灭杀活性。3,4-二氯苄胺衍生物对多刺菱形藻、赤潮藻、海洋Chattonella以及圆形裙藻显示出较高的活性，而合成的化合物27、28、33、34、35和36在0.1 ~ 1.0 μM LC50条件下，在24小时后对这四种有害藻类展现出最高的藻类灭杀活性。为了验证这些化合物的安全性，我们进行了使用水蚤（Daphnia magna）和斑马鱼（Danio rerio）的急性生态毒理学测试，结果表明化合物33和34并不有害，因为目标生物在15 μM浓度下显示出较高的生存率。这些结果表明化合物33和34适合作为控制有害藻类的物质。
• [EN] BICYCLIC QUINAZOLINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINAZOLINONE BICYCLIQUE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016162390A1

  公开（公告）日：2016-10-13

  The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12, R13, R14, A1, A2, A3, n and m are as described herein.

  该发明提供了具有一般式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R12、R13、R14、A1、A2、A3、n和m如本文所述。
• COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS
  申请人：CUREARTH, INC.

  公开号：US20180271091A1

  公开（公告）日：2018-09-27

  The present disclosure relates to a composition for the destruction of microalgae or mosses. The composition for the destruction of microalgae or mosses may suppress the growth and proliferation of microalgae when treated in moss cultivation facilities, marine microalgae cultivation facilities, areas in which green or red tide is occurring, or areas in which green or red tide is expected to occur, thereby preventing damage caused by the green or red tide.

  本公开涉及一种用于消灭微藻或苔藓的组合物。该用于消灭微藻或苔藓的组合物在苔藓培育设施、海洋微藻培育设施、发生绿潮或红潮的区域，或者预计会发生绿潮或红潮的区域中处理时，可以抑制微藻的生长和繁殖，从而预防绿潮或红潮造成的损害。
• Compounds which inhibit leukocyte adhesion mediated by VLA-4
  申请人：Konradi W. Andrei

  公开号：US20050261293A1

  公开（公告）日：2005-11-24

  Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本发明涉及一种能够结合VLA-4的化合物。其中某些化合物还能够抑制白细胞黏附，特别是通过VLA-4介导的白细胞黏附。这样的化合物可用于治疗哺乳动物患者（例如人类）的炎症性疾病，例如哮喘、阿尔茨海默病、动脉硬化、艾滋病痴呆、糖尿病、炎性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物还可用于治疗多发性硬化等炎症性脑部疾病。